In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 3988-4000

  Louie, Arnold ^a   Brown, David L ^a   Liu, Weiguo ^a   Kulawy, Robert W ^a   Deziel, Mark R ^a   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; ETHIDIUM BROMIDE; LEVOFLOXACIN; RESERPINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT; CIPROFLOXACIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; ETHIDIUM; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; RESERPINE; STREPTOCOCCUS PNEUMONIAE;

EID: 35848938329     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00391-07     Document Type: Article

References (17)

1. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
2. Chen, D. K., A. McGreer, J. C. De Azevedo, D. E. Low, et al. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
3. Chien, S. C., M. C. Rogge, L. G. Gisclon, C. Curtin, F. Wong, J. Natarajan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. T. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
4. Cirz, R. T., J. K. Chin, D. R. Andes, V de Crecy-Lagard, W. A. Craig, and F. E. Romesberg. 2005. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 3:e176.
5. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. de Azavedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750.
6. Gill, M. J., N. P. Brewald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
7. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses Mycobacterium tuberculosis resistance using an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
8. Jumbe, N. L., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in-vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
9. Jumbe, N. L., A. Louie, M. H. Miller, W. Liu, M. R. Deziel, V. H. Tam, R. Bacbhawat, and G. L. Drusano. 2006. Quinolone efflux pumps play a central role in emergence of resistance to fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:310-317.
10. Lacy, M. K., W. Lu, X. Xu, P. R. Tessier, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43:672-677.
11. Lubasch, A., I. Keller, K. Borner, P. Koeppe, and H. Lode. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44:2600-2603.
12. Markham, P. N. 1999. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob. Agents Chemother. 43:988-989.
13. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
14. Piddock, L. J. V., and M. M. Johnson. 2002. Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:813-820.
15. Ross, G. H., L. Baeker Hovde, K. H. Ibrahim, Y. H. Ibrahim, and J. C. Rotschafer. 2001. Comparison of once-daily versus twice-daily administration of cefdinir against typical bacterial respiratory tract pathogens. Antimicrob. Agents Chemother. 45:2936-2938.
16. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, R. Leary, and G. L. Drusano. 2005. Bacterial population responses to drug selective pressure: examination of garenoxacin against Pseudomonas aeruginosa. J. Infect. Dis. 192:420-428.
17. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P. R. Cieslak, M. Cetron, E. R. Zell, J. H. Jorgenson, A. Schuchat, and the Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. 2000. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917-1924.